Paraprotéines et atteintes réenales
|Published in||Revue médicale suisse. 2010, vol. 6, no. 238, p. 460-466|
|Abstract||Paraproteinaemia is frequent in the population above 50 years of age. It is commonly associated in patients with multiple myeloma with diverse renal involvements, such as cast nephropathy, light chain deposition disease, amyloidosis and Fanconi syndrome. A rapid diagnosis is necessary to implement a specific and aggressive treatment in order to prevent development of end-stage renal disease. Plasma exchanges or daily dialysis with high-cut off filter associated with chemotherapy may decrease the plasmatic concentration and production of monoclonal light chains. Bortezomib, thalidomide and lenalidomide are promising therapeutic agents, whose effects in patients with myeloma-associated renal diseases should be more thoroughly studied. Autologous hematopoietic cell transplantation remains the standard of care treatment for eligible patients.|
|Keywords||Biopsy — Humans — Kidney/pathology — Kidney Diseases/*complications/therapy — Paraproteinemias/*complications/diagnosis/therapy — Prognosis|
This document has no fulltext available yet, but you can contact its author by using the form below.
|GRANDJEAN, Anne Pascale, DETTWILER, Sarah, SAUDAN, Patrick. Paraprotéines et atteintes réenales. In: Revue médicale suisse, 2010, vol. 6, n° 238, p. 460-466. https://archive-ouverte.unige.ch/unige:20475|